公开(公告)号：USD719712S1

公开(公告)日：2014-12-16

申请号：US29431444

申请日：2012-09-07

申请人： Alfred Widmer ,  Mehmet Avci ,  Axel Schmitz ,  Andrew M. Bober ,  Michael Bachmann ,  Andreas Staub ,  Markus Zbinden

设计人： Alfred Widmer ,  Mehmet Avci ,  Axel Schmitz ,  Andrew M. Bober ,  Michael Bachmann ,  Andreas Staub ,  Markus Zbinden

CPC分类号： A46B17/00 ,  A46B2200/00 ,  A46B2200/30 ,  A46B2200/3033

公开(公告)号：US20120251554A1

公开(公告)日：2012-10-04

申请号：US13497800

申请日：2010-09-22

申请人： Michael Bachmann ,  Slava Stamova

发明人： Michael Bachmann ,  Slava Stamova

IPC分类号： A61K39/395 ,  C12N9/96 ,  C12N15/13 ,  C12N15/63 ,  A01K67/027 ,  C12P21/02 ,  C12N1/19 ,  C12N5/10 ,  A01H5/00 ,  A01K67/033 ,  C07K16/28 ,  C12N1/21

CPC分类号： C07K16/2803 ,  C07K16/2809 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/626

摘要： The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 1010 mol/l. The CDR sequences according to the invention are suitable in particular for producing recombinant fragments (such as scFv fragments or bispecific antibodies) and for immunotargeting, due to the high affinity thereof. The invention further relates to the use of an antibody according to the invention for producing a medication for therapeutic and/or diagnostic application for illnesses associated with the expression of CD33, particularly for acute myeloid leukemia (AML). The invention thus also comprises a pharmaceutical composition comprising one or more antibodies according to the invention in association with a pharmaceutically acceptable thinning agent or carrier.

摘要翻译： 本发明涉及肿瘤相关抗原CD33的抗体及其用于免疫靶向CD33阳性细胞的用途。 根据本发明的抗体适用于医药，药物和生物医学研究领域。 根据本发明，目的是通过包含权利要求中定义的互补决定区（CDR）的新型抗CD33抗体来实现。 根据本发明的抗体的特征在于对人CD33的高亲和力，其数量级为1010mol / l。 由于其高亲和力，根据本发明的CDR序列特别适用于产生重组片段（例如scFv片段或双特异性抗体）和免疫靶向。 本发明还涉及根据本发明的抗体用于产生用于与CD33表达相关的疾病的治疗和/或诊断应用的药物的用途，特别是用于急性骨髓性白血病（AML）。 因此，本发明还包含与药学上可接受的稀释剂或载体结合的包含根据本发明的一种或多种抗体的药物组合物。

公开(公告)号：US09487585B2

公开(公告)日：2016-11-08

申请号：US13814512

申请日：2011-08-05

申请人： Michael Bachmann ,  Daniel Gräfe

发明人： Michael Bachmann ,  Daniel Gräfe

IPC分类号： C12P21/08 ,  C07K16/00 ,  C07K16/28 ,  A61K9/00 ,  A61K38/10 ,  A61K39/00 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K9/0019 ,  A61K38/10 ,  A61K39/0011 ,  A61K39/39533 ,  A61K39/3955 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/92

摘要： The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N, CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).

摘要翻译： 本发明涉及含有至少一种抗唾液酸抗体及其诊断和治疗用途的组合物。 根据本发明的组合物包含：a）至少一种抗蝙蝠抗体，b）至少一个结合单元，其结合共刺激与树突状细胞上的共刺激特异性受体的结合，由此引起调节 ，优选活化所述树突状细胞，和c）至少一种抗原。 本发明还包括抗an抗体，其包括具有以下序列的CDR：重链可变区：CDR1（SEQ ID No.1），CDR2（SEQ ID No.2），其中Xaa选自M，L ，F或I，优选M或I，CDR3（SEQ ID No.5）和轻链可变区：CDR1（SEQ ID No.6），其中Xaa选自S，T，N， Q，H，K或R，优选来自S或N，CDR2（SEQ ID No.9）和CDR3（SEQ ID No.10）。

公开(公告)号：US09200078B2

公开(公告)日：2015-12-01

申请号：US14129933

申请日：2012-06-29

申请人： Michael Bachmann

发明人： Michael Bachmann

IPC分类号： C07K16/30 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/3069 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/92

摘要： The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumor diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.

摘要翻译： 本发明涉及结合前列腺特异性干细胞抗原（PSCA）的重组抗体。 本发明的抗体包含具有以下氨基酸序列的互补决定区（CDR）：轻链可变区的CDR：CDR1 SEQ ID No.1，CDR2 SEQ ID No.2，CDR3 SEQ ID No.3 和CDR的重链可变区的CDR：CDR1 SEQ ID No.4，CDR2 SEQ ID No.5，CDR3 SEQ ID No.6。本发明还包括使用本发明的抗体作为药用产品，特别是 用于治疗肿瘤疾病，或作为诊断剂。 该抗体适用于医药，药学和生物医学研究领域。

公开(公告)号：US08196520B2

公开(公告)日：2012-06-12

申请号：US12668240

申请日：2008-07-03

申请人： Michael Holzapfel ,  Michael Bachmann ,  Heike Smula ,  Heiko Mühlberg

发明人： Michael Holzapfel ,  Michael Bachmann ,  Heike Smula ,  Heiko Mühlberg

IPC分类号： B61C9/00

CPC分类号： B61C9/50 ,  B61F3/06 ,  B61F5/02

摘要： A bogie for a locomotive comprising a bogie frame and at least one wheel set including two wheels, a wheel set gear, a wheel set shaft and a wheel set gear housing. A push/pull rod acts on one side of the bogie frame and on the other side of locomotive frame and transfers forces between the two. The gear housing of the wheel set exhibits a recess for the feeding through of the push/pull rod, the recess being bordered by walls which are integral with the remaining housing walls.

摘要翻译： 一种用于机车的转向架，包括转向架框架和至少一个包括两个轮子的轮组，轮组齿轮，轮组轴和轮组齿轮壳体。 推/拉杆作用在转向架框架的一侧和机车框架的另一侧，并在两者之间传递力。 车轮组的齿轮壳体具有用于通过推/拉杆进给的凹部，该凹部由与其余壳体壁成一体的壁边界。

公开(公告)号：US20070299581A1

公开(公告)日：2007-12-27

申请号：US11630090

申请日：2005-05-10

申请人： Antonio Torralbo ,  Michael Bachmann

发明人： Antonio Torralbo ,  Michael Bachmann

IPC分类号： G05D3/12

CPC分类号： B60T7/122 ,  B60T8/00

摘要： A method for limiting motor-vehicle rollback includes steps in which: the drive direction of the vehicle belonging to the engaged gear step, i.e., transmission step, is determined; the direction of movement of the vehicle is determined; and in the case when the direction of movement is opposite the drive direction, a braking intervention is implemented independently of the driver at the wheels of at least one axle.

摘要翻译： 一种用于限制机动车辆回退的方法包括以下步骤：确定属于接合齿轮步骤的车辆的驱动方向，即传动步骤; 确定车辆的运动方向; 并且在运动方向与驱动方向相反的情况下，独立于至少一个车轴的车轮处的驾驶员实现制动干预。

公开(公告)号：US09540446B2

公开(公告)日：2017-01-10

申请号：US13814510

申请日：2011-08-05

申请人： Michael Bachmann

发明人： Michael Bachmann

IPC分类号： C07K16/30 ,  C07K16/28 ,  C07K16/18

CPC分类号： C07K16/30 ,  C07K16/18 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73

摘要： The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumor cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumor cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumor cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.

摘要翻译： 本发明涉及抗人类La蛋白的抗体及其在免疫靶向中的用途，特别是肿瘤细胞的免疫靶向。 本发明的目的是提供改进的抗体，其结合肿瘤细胞表面上的通用靶结构，并提供新的抗-La抗体，特别是对La的肿瘤细胞上的通用靶结构具有高亲和力，其使得 可以将抗体用作免疫靶向的重组片段。 本发明包括重组抗体，其包含： 特异性结合人核抗原，优选人La蛋白的表位的抗体的结合单元，和ii。 特异性结合效应细胞或特异性结合效应细胞的配体的抗体的结合单元。 本发明还包括与人La蛋白特异性结合的新型抗体。

公开(公告)号：US08938346B2

公开(公告)日：2015-01-20

申请号：US13818732

申请日：2011-08-30

申请人： Raphael Oliveira ,  Michael Bachmann

发明人： Raphael Oliveira ,  Michael Bachmann

IPC分类号： B60T7/12

CPC分类号： B60T7/12 ,  B60T7/122 ,  B60T2201/06

摘要： A method for holding a vehicle at a standstill includes a first phase in which the brake pressure at the wheel brakes is retained so that the vehicle is held automatically by the service brake, and the braking force is then transferred to a parking brake so that in a second phase the vehicle is held solely by the parking brake. A risk inherent in this transfer is that the vehicle may begin to slip. The distance over which the vehicle slides in uncontrolled fashion can be made substantially shorter if, in the second phase in which the vehicle is being held by the parking brake, the movement of the vehicle is monitored by sensors, and brake pressure is automatically built up by way of an actuator as soon as the fact that the vehicle is rolling away has been detected.

摘要翻译： 用于将车辆保持在停止状态的方法包括第一阶段，其中保持车轮制动器处的制动压力，使得车辆被行车制动器自动保持，然后制动力被传递到驻车制动器，使得在 车辆仅由驻车制动器保持的第二阶段。 这种转移固有的风险是车辆可能开始滑落。 如果车辆由驻车制动器保持的第二阶段中车辆的运动由传感器监控，则车辆以不受控制的方式滑动的距离可以大大缩短，并且制动压力被自动建立 一旦检测到车辆正在滚动的事实，就通过致动器。

公开(公告)号：US20150299312A1

公开(公告)日：2015-10-22

申请号：US13814512

申请日：2011-08-05

申请人： Michael Bachmann ,  Daniel Grafe

发明人： Michael Bachmann ,  Daniel Grafe

IPC分类号： C07K16/28 ,  A61K38/10 ,  A61K39/00 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K9/0019 ,  A61K38/10 ,  A61K39/0011 ,  A61K39/39533 ,  A61K39/3955 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/92

摘要： The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N,CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).

摘要翻译： 本发明涉及含有至少一种抗唾液酸抗体及其诊断和治疗用途的组合物。 根据本发明的组合物包含：a）至少一种抗蝙蝠抗体，b）至少一个结合单元，其结合共刺激与树突状细胞上的共刺激特异性受体的结合，由此引起调节 ，优选活化所述树突状细胞，和c）至少一种抗原。 本发明还包括抗an抗体，其包括具有以下序列的CDR：重链可变区：CDR1（SEQ ID No.1），CDR2（SEQ ID No.2），其中Xaa选自M，L ，F或I，优选M或I，CDR3（SEQ ID No.5）和轻链可变区：CDR1（SEQ ID No.6），其中Xaa选自S，T，N， Q，H，K或R，优选来自S或N，CDR2（SEQ ID No.9）和CDR3（SEQ ID No.10）。

公开(公告)号：US20140134155A1

公开(公告)日：2014-05-15

申请号：US14129933

申请日：2012-06-29

申请人： Michael Bachmann

发明人： Michael Bachmann

IPC分类号： C07K16/30

CPC分类号： C07K16/3069 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/92

摘要： The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumour diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.

摘要翻译： 本发明涉及结合前列腺特异性干细胞抗原（PSCA）的重组抗体。 本发明的抗体包含具有以下氨基酸序列的互补决定区（CDR）：轻链可变区的CDR：CDR1 SEQ ID No.1，CDR2 SEQ ID No.2，CDR3 SEQ ID No.3 和CDR的重链可变区的CDR：CDR1 SEQ ID No.4，CDR2 SEQ ID No.5，CDR3 SEQ ID No.6。本发明还包括使用本发明的抗体作为药用产品，特别是 用于治疗肿瘤疾病，或作为诊断剂。 该抗体适用于医药，药学和生物医学研究领域。